Oragenics (OGEN) Share-based Compensation (2010 - 2026)
Oragenics' (OGEN) quarterly Share-based Compensation came in at $190615.0 in Q1 2026, up 976.56% YoY from $17706.0 in Q1 2025, and down 63.71% on a QoQ basis from $525222.0 in Q4 2025.
Oragenics (OGEN) Share-based Compensation (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Share-based Compensation data on file, last reported at $190615.0 in Q1 2026.
- Quarterly Share-based Compensation rose 976.56% year-over-year to $190615.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $190615.0 (down 59.92% YoY) and the FY2025 annual result came in at $555747.0, up 7.69% from the prior year.
- Share-based Compensation retreated to $190615.0 in Q1 2026, from $525222.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $525222.0 in Q4 2025 to a low of -$95577.0 in Q4 2022.
- A 5-year average of $145160.4 and a median of $79966.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 141.13% — and 2024, when it surged 1518.49%.
- Tracing OGEN's Share-based Compensation over 5 years: stood at -$95577.0 in 2022, then soared by 103.73% to $3564.0 in 2023, then surged by 1518.49% to $57683.0 in 2024, then soared by 810.53% to $525222.0 in 2025, then sank by 63.71% to $190615.0 in 2026.
- The last three Share-based Compensation figures came in at $190615.0 (Q1 2026), $525222.0 (Q4 2025), and $6040.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | - |
| 10 | Oragenics | 2.36 Mn | 2.36 Mn | - | 173,034.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 173,034.00 |
| Jun 30, 2026 | 173,034.00 |
| Mar 31, 2026 | 190,615.00 |
| Mar 31, 2026 | 190,615.00 |
| Dec 31, 2025 | 525,222.00 |
| Dec 31, 2025 | 525,222.00 |
| Sep 30, 2025 | 6,040.00 |
| Sep 30, 2025 | 6,040.00 |
| Jun 30, 2025 | 6,779.00 |
| Jun 30, 2025 | 6,779.00 |
| Mar 31, 2025 | 17,706.00 |
| Mar 31, 2025 | 17,706.00 |
| Dec 31, 2024 | 57,683.00 |
| Dec 31, 2024 | 57,683.00 |
| Sep 30, 2024 | 330,802.00 |
| Sep 30, 2024 | 330,802.00 |
| Jun 30, 2024 | 160,927.00 |
| Jun 30, 2024 | 160,927.00 |
| Mar 31, 2024 | 69,344.00 |
| Mar 31, 2024 | 69,344.00 |